A case of severe bacteremic pneumococcal pneumonia which developed in a patient with lung cancer, whowas taking ofloxacin for chemoprophylaxis, is presented. Pneumonia resolved well with intravenous penicillin G. Infection by and colonization with Streptococcus pneumoniaemight becomea problem with increasing use of the fluoroquinolones.
ofloxacin, enoxacin and ciprofloxacin have a broad spectrum of activity against gram-negative and gram-positive bacteria and are currently being investigated as to their efficacy in the treatment of lower respiratory infections (1-3).
The new quinolones are also used for prophylaxis of bacterial infections in patients with granulocytopenia because they eliminate the aerobic gram-negative flora of the gastrointestinal tract while preserving the anaerobic flora. However, the quinolones have been reported to be ineffective for prevention of gram-positive infections, caused mainly by streptococci and coagulase-negative staphylococci (4, 5 Twodays after admission, S. pneumoniaegrew from a blood culture. Antibiotic regimen was switched to penicillin G and ceftriaxone which was discontinued four days later. Subsequent chest x-ray films showed progressive bilateral improvement.
Although he was eventually weaned from a ventilator, his subsequent hospital course was complicated by tumor progression and pneumonia caused by Pseudomonas aeruginosa, and he died on the sixty-second hospital day. pneumonia was not mentioned (4). Our patient experienced severe bacteremic pneumococcal pneumonia while receiving ofloxacin for antimicrobial prophylaxis. S. pneumoniae is one of the major pathogens causing bacteremia with a high mortality rate in cancer patients (6) . Whether the wide use of the fluoroquinolones for chemoprophylaxis will increase pneumococcal infection must be monitored closely.
The new quinolones are also being investigated in the treatment of lower respiratory tract infections because of their broad spectrum activity against most important respiratory pathogens and their good penetration into bronchial secretions. Although one drawback of the fluoroquinolones is that their in vitro activity against S. pneumoniae is marginal, their efficacy in the treatment of pneumococcal pneumonia has been fairly good in reported studies (1 , 2) . However, failure to eradicate S. pneumoniae has been reported (3). It is recommended that fluoroquinolones should not be used in the treatment of lower respiratory tract infections when S. pneumoniae is considered to be the most likely pathogen (3) . Our case report supports this recommendation because ofloxacin cannot prevent pneumococcal infection.
